147 related articles for article (PubMed ID: 16475028)
1. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
Qu CF; Song EY; Li Y; Rizvi SM; Raja C; Smith R; Morgenstern A; Apostolidis C; Allen BJ
Clin Exp Metastasis; 2005; 22(7):575-86. PubMed ID: 16475028
[TBL] [Abstract][Full Text] [Related]
2. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
Li Y; Rizvi SM; Ranson M; Allen BJ
Br J Cancer; 2002 Apr; 86(7):1197-203. PubMed ID: 11953871
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.
Allen BJ; Tian Z; Rizvi SM; Li Y; Ranson M
Br J Cancer; 2003 Mar; 88(6):944-50. PubMed ID: 12644835
[TBL] [Abstract][Full Text] [Related]
4. Targeted alpha therapy for cancer.
Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
[TBL] [Abstract][Full Text] [Related]
5. Targeted alpha therapy approach to the management of pancreatic cancer.
Allen BJ; Rizvi SM; Qu CF; Smith RC
Cancers (Basel); 2011 Apr; 3(2):1821-43. PubMed ID: 24212784
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Qu CF; Songl YJ; Rizvi SM; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ
Cancer Biol Ther; 2005 Aug; 4(8):848-53. PubMed ID: 16082185
[TBL] [Abstract][Full Text] [Related]
7. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Li Y; Abbas Rizvi SM; Blair nee Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJ; Allen BJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):896-908. PubMed ID: 15465208
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.
Abbas Rizvi SM; Li Y; Song EY; Qu CF; Raja C; Morgenstern A; Apostolidis C; Allen BJ
Cancer Biol Ther; 2006 Apr; 5(4):386-93. PubMed ID: 16575210
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer.
Song EY; Abbas Rizvi SM; Qu CF; Raja C; Brechbiel MW; Morgenstern A; Apostolidis C; Allen BJ
Cancer Biol Ther; 2007 Jun; 6(6):898-904. PubMed ID: 17582216
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.
Song YJ; Qu CF; Rizvi SM; Li Y; Robertson G; Raja C; Morgenstern A; Apostolidis C; Perkins AC; Allen BJ
Cancer Lett; 2006 Mar; 234(2):176-83. PubMed ID: 15961220
[TBL] [Abstract][Full Text] [Related]
11. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
12. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.
Wang J; Abbas Rizvi SM; Madigan MC; Cozzi PJ; Power CA; Qu CF; Morgenstern A; Apostolidis C; Russell PJ; Allen BJ; Li Y
Prostate; 2006 Dec; 66(16):1753-67. PubMed ID: 16955401
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.
Jin Y; Liang ZY; Zhou WX; Zhou L
Hepatol Int; 2019 Mar; 13(2):180-189. PubMed ID: 30600477
[TBL] [Abstract][Full Text] [Related]
14. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.
Ranson M; Tian Z; Andronicos NM; Rizvi S; Allen BJ
Breast Cancer Res Treat; 2002 Jan; 71(2):149-59. PubMed ID: 11881911
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
17. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
20. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA.
He X; Zheng Z; Li J; Ben Q; Liu J; Zhang J; Ji J; Yu B; Chen X; Su L; Zhou L; Liu B; Yuan Y
Carcinogenesis; 2012 Mar; 33(3):555-62. PubMed ID: 22223849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
